Phase I/IIa Study of Descartes-25 in Patients With Relapsed/Refractory Multiple Myeloma
Phase I/IIa Study of Descartes-25 in Patients With Relapsed/Refractory Multiple Myeloma
This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple Myeloma.
Inclusion Criteria:
Exclusion Criteria:
- Patients with active plasma cell leukemia